Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

Pietro A. Canetta, MD, illustrates how treating patients with IgA nephropathy is an exciting opportunity as treatment options have greatly expanded in recent decades. Today, FDA-approved drugs are ...

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Campari (LON:0ROY) Group reported its Q4 2024 earnings, highlighting a steady organic top-line growth of 2.4% for the full year, with total growth reaching 5.2%. Despite a challenging global ...

It’s important to carefully check the trims of the car you’re interested in to make sure that you’re getting the features you want, and aren’t overpaying for those you don’t want. Our ...

U.S. President Donald Trump is applauded at the White House Crypto Summit at the White House in Washington, D.C., U.S., March 7, 2025. REUTERS/Evelyn Hockstein U.S. President Donald Trump wooed ...

3382.T Seven & i Holdings Co., Ltd.